SGLT2 inhibitor

New therapies show promise in treating diabetes
New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
Serious risks associated with SGLT2 inhibitorsFDA is warning about ketoacidosis and urinary tract infections associated with the relatively new class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors such as Invokana and Jardiance.
FDA increases warning on diabetes medicationThe FDA has strengthened its warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and added new information about decreased bone mineral density.
SGLT2 inhibitors: New drug therapy for type 2 diabetes may carry acidosis riskFDA has issued a warning about a possible link between use of SGLT2 inhibitors and ketoacidosis.
SGLT2 inhibitors for diabetes may cause ketoacidosis, FDA warnsThe FDA is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization.
What's on the horizon for diabetes therapy?SGLT2 inhibitors, GLP-1 receptor agonists, inhaled insulin, extended-release treatments, and fixed-dose combination therapies are among the approaches that have emerged to treat the exploding numbers of type 2 diabetes patients.
FDA approves combo pill for adults with type 2 diabetesFDA has approved once-daily dapagliflozin and metformin hydrochloride extended-release (Xigduo, AstraZeneca) (XR) for the treatment of adults with type 2 diabetes. Xigduo XR is indicated as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.
Another SGLT2 inhibitor for type 2 diabetes is approvedFDA has approved empagliflozin (Jardiance, Boehringer Ingelheim Pharmceuticals) as another option for adult patients with type 2 diabetes.